PepGen Inc. is a biotechnology firm focused on the development of innovative therapies for treating genetic diseases
Utilizing its proprietary peptide-based technology platform, the company aims to advance the treatment options for patients suffering from a range of neuromuscular and central nervous system disorders. PepGen is dedicated to harnessing the power of targeted delivery of genetic medicines to improve patient outcomes and support the growing demand for effective gene therapies in the healthcare landscape. Through rigorous research and development, PepGen seeks to bring transformative solutions to underserved medical needs.
PepGen halts its Phase 2 CONNECT2 trial for PGN-EDO51 in DMD to assess 10 mg/kg cohort data, while advancing FREEDOM-DM1 studies in myotonic dystrophy.
The regular session of the US market on Thursday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
Intrigued by the market activity in the middle of the day on Thursday? Uncover the key winners and losers of today's session in our insightful analysis.
Intrigued by the market activity one hour before the close of the markets on Monday? Uncover the key winners and losers of today's session in our insightful analysis.
